Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-18T22:48:55.973Z Has data issue: false hasContentIssue false
  • English
  • Français

Iatrogenic causes of an ICH: OAT therapy

Published online by Cambridge University Press:  01 February 2008

A. Iorio
A. Iorio*
Affiliation:
Università di Perugia, Sezione di Medicina Interna e Cardiovascolare, Stroke Unit, Dipartimento di Medicina Interna, Perugia, Italy
*
Correspondence to: Alfonso Iorio, Dipartimento di Medicina Interna, Stroke Unit, Sezione di Medicina Interna e Cardiovascolare, Università di Perugia, Perugia, Italy. E-mail: iorioa@unipg.it; Tel: +39 348 9378046/+39 349 1204 919; Fax: +39 178 22 18 383
Get access

Summary

Current understanding of oral anticoagulant treatment and related intracerebral haemorrhage remains rather limited as compared to that of spontaneous intracerebral haemorrhage. Although intracerebral haemorrhage is the most serious complication of oral anticoagulant treatment, standardized treatment guidelines are still lacking. The currently employed treatments are aimed at normalization of the iatrogenic coagulation impairment, and are not based on randomized controlled trials evidence. Since most patients with oral anticoagulant treatment-intracerebral haemorrhage are at high risk of cardio-embolism and often myocardial infarction, it is uncertain whether the use of procoagulant treatments for oral anticoagulant treatment-intracerebral haemorrhage may increase their risk of thrombotic complications. Patients who receive chronic oral anticoagulant treatment urgently require effective treatments for acute oral anticoagulant treatment-intracerebral haemorrhage, and therefore controlled clinical trials are needed.

Keywords

CEREBRAL HAEMORRHAGEANTICOAGULANT AGENTS, oral4-HYDROXYCOUMARINSFACTOR VII, recombinant
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 25 , Issue S42 , February 2008 , pp. 8 - 11
Copyright
Copyright © European Society of Anaesthesiology 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Sudlow, CL, Warlow, CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke 1997; 28: 491–499.CrossRefGoogle ScholarPubMed
2.Carolei, A, Marini, C, Di Napoli, M et al. . High stroke incidence in the prospective community-based l’Aquila registry (1994–1998): first year’s result. Stroke 1997; 28: 2500–2506.CrossRefGoogle Scholar
3.Baldi, G, Altomonte, F, Altomonte, M, Ghirarduzzi, A, Brusasco, C, Iorio, RCA. Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. Cerebrovasc Dis 2006; 22: 286–293.CrossRefGoogle Scholar
4.Dennis, MS. Outcome after brain haemorrhage. Cerebrovasc Dis 2003; 16: 9–13.CrossRefGoogle ScholarPubMed
5.Kothari, RU, Brott, T, Broderick, JP et al. . The ABCs of measuring intracerebral hemorrhage volumes. Stroke 1996; 27: 1304–1305.CrossRefGoogle ScholarPubMed
6.Hart, RG, Boop, BS, Anderson, DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypothesis. Stroke 1995; 26: 1471–1477.Google Scholar
7.Landerfeld, CS, Beyth, RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315–328.CrossRefGoogle Scholar
8.Oden, A, Fahlen, M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002; 325: 1073–1075.CrossRefGoogle Scholar
9.Mattle, H, Kohler, S, Huber, P, Rohner, M, Steinsiepe, KF. Anticoagulation related intracranial extracerebral hemorrhage. J Neurol Neurosurg Psychiatry 1989; 52: 829–837.CrossRefGoogle Scholar
10.Hankey, GJ, Eikelboom, JW. Antiplatelet drugs. Med J Aust 2003; 178: 568–574.Google Scholar
11.Ansell, J, Hirsh, J, Poller, L, Bussey, H, Jacobson, A, Hylek, E. The pharmacology and management of the vitamin K antagonists. Chest 2004; 126: 204S–233S.CrossRefGoogle ScholarPubMed
12.The European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) Study Group. Oral anticoagulation in patients after cerebral ischaemia of arterial origin and risk of intracranial hemorrhage. Stroke 2003; 34: e45–e47.Google Scholar
13.Abbott, RD, Curb, JD, Rodriguez, BL et al. . Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke. J Clin Epidemiol 2003; 56: 479–486.CrossRefGoogle ScholarPubMed
14.Palareti, G, Leali, N, Coccheri, S et al. . Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423–428.CrossRefGoogle ScholarPubMed
15.Nicolini, A, Ghirarduzzi, A, Iorio, A, Silingardi, M, Malferrari, G, Baldi, G. Intracranial bleeding: epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. Haematologica 2002; 87: 948–956.Google ScholarPubMed
16.Hart, RG. What causes intracerebral hemorrhage during warfarin therapy? Neurology 2000; 55: 907–908.CrossRefGoogle ScholarPubMed
17.Roob, G, Schmidt, R, Kapeller, P, Lechner, A, Hartung, HP, Fazekas, F. MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology 1999; 52: 991–994.CrossRefGoogle Scholar
18.Rosand, J, Hylek, EM, O’Donnell, HC, Greenberg, SM. Warfarin associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000; 55: 947–951.CrossRefGoogle ScholarPubMed
19.Yasaka, M, Minematsu, K, Yamaguchi, T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183–1188.CrossRefGoogle ScholarPubMed
20.Rosand, J, Eckman, MH, Knudsen, KA, Singer, DE, Greenberg, SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164: 880–884.CrossRefGoogle ScholarPubMed
21.Nilsson, OG, Lindgren, A, Stahl, N, Brandt, L, Saveland, H. Incidence of intracerebral and subarachnoid haemorrhage in southern Sweden. J Neurol Neurosurg Psychiatry 2000; 69: 601–607.CrossRefGoogle ScholarPubMed
22. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation, Analysis of pooled data from five randomized controlled trials. Arch Intern Med, 1994; 154: 1449–1457.CrossRefGoogle Scholar
23.Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156: 409–416.CrossRefGoogle Scholar
24.Hylek, E, Singer, DE. Risk factor for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897–902.CrossRefGoogle ScholarPubMed
25.Flibotte, JJ, Hagan, N, O’Donnell, J, Greenberg, SM, Rosand, J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63: 1059–1064.CrossRefGoogle ScholarPubMed
26.Brott, T, Broderick, J, Kothari, R et al. . Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28: 1–5.CrossRefGoogle ScholarPubMed
27.Leira, R, Davalos, A, Silva, Y et al. . Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology 2004; 63: 461–467.CrossRefGoogle ScholarPubMed
28.Butler, AC, Tait, RC. Management of oral anticoagulant-induced intracranial haemorrhage. Blood Rev 1998; 12: 35–44.CrossRefGoogle ScholarPubMed
29.Boulis, NM, Bobek, MP, Schmaier, A, Hoff, JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45: 1113–1118.CrossRefGoogle ScholarPubMed
30.Freeman, WD, Brott, TG, Barrett, KM et al. . Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004; 79: 1495–1500.Google Scholar
31.Fewel, ME, Park, P. The emerging role of recombinant-activated factor VII in neurocritical care. Neurocritical Care 2004; 1: 19–30.CrossRefGoogle ScholarPubMed
32.Baglin, TP, Rose, PE, Walker, ID et al. . Guidelines on oral anticoagulation: third edition. Br J Haemato 1998; 101: 374–387.Google Scholar
33.Ansell, J, Hirsh, J, Dalen, J et al. . Managing oral anticoagulant therapy. Chest 2001; 119: 22S–38S.CrossRefGoogle ScholarPubMed
34.Phan, TG, Koh, M, Wijdicks, EF. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol 2000; 57: 1710–1713.CrossRefGoogle ScholarPubMed
35.Ananthasubramaniam, K, Beattie, JN, Rosman, HS, Jayam, V, Borzak, S. How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage? Chest 2001; 119: 478–484.CrossRefGoogle Scholar
36.Bertram, M, Bonsanto, M, Hacke, W, Schwab, S. Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. J Neuro 2000; 247: 209–214.CrossRefGoogle ScholarPubMed
37.Hacke, W. The dilemma of anticoagulation for patients with intracranial hemorrhage or how wide is the strait between Skylla and Karybdis? (Editorial). Neurology 2000; 57: 1682–1684.Google ScholarPubMed
38.Eckman, MH, Rosand, J, Knudsen, KA, Singer, DE, Greenberg, SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003; 34: 1710–1716.CrossRefGoogle ScholarPubMed
39.Wijdicks, EF, Diringer, MN. Middle cerebral artery territory infarction and early brain swelling: progression and effect of age on outcome. Mayo Clin Proc 1998; 73: 829–836.CrossRefGoogle ScholarPubMed
40.Beeck, H, Hellstern, P. In vitro characterization of solvent/detergent treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998; 74: 219–223.Google Scholar
41.Hanley, JP. Warfarin reversal. J Clin Pathol 2004; 57: 1132–1139.Google Scholar
42.Bianco, C. Choice of human plasma preparations for transfusion. Transfus Med Rev 1999; 13: 84–88.CrossRefGoogle ScholarPubMed
43.Makris, M, Greaves, M, Phillips, WS, Kitchen, S, Rosendaal, FR, Preston, EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477–480.Google Scholar
44.Pindur, G, Morsdorf, S, Schenk, JF, Krischek, B, Heinrich, W, Wenzel, E. The overdosed patient and bleedings with oral anticoagulation. Semin Thromb Hemost 1999; 25: 85–88.Google Scholar
45.Hellstern, P, Muntean, W, Schramm, W, Seifried, E, Solheim, BG. Practical guidelines for the clinical use of plasma. Thromb Res 2002; 107: S53–S57.Google Scholar
46.O’Shaughnessy, DF, Atterbury, C, Bolton Maggs, P et al. . Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11–28.Google ScholarPubMed
47.Gilstad, CW. Anaphylactic transfusion reactions. Curr Opin Hematol 2003; 10: 419–423.Google Scholar
48.Pomper, GJ, Wu, Y, Snyder, EL. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol 2003; 10: 412–418.CrossRefGoogle ScholarPubMed
49.Boulis, NM, Bobek, MP, Schmaier, A, Hoff, JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45: 1113–1118.CrossRefGoogle ScholarPubMed
50.Fredriksson, K, Norrving, B, Stromblad, LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23: 972–977.CrossRefGoogle ScholarPubMed
51.Sjoblom, L, Hardemark, HG, Lindgren, A et al. . Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001; 32: 2567–2574.CrossRefGoogle ScholarPubMed
52.McNeill, SA, Ewing, JC, Wallace, WA, Stewart, LH. Venous infarction of a testicle following factor IX concentrate (DEFIX). Br J Haematol 1998; 101: 210.CrossRefGoogle ScholarPubMed
53.Roddie, PH, Stirling, C, Mayne, EE, Ludlam, CA. Thrombosis and disseminated intravascular coagulation following treatment with the prothrombin complex concentrate, DEFIX. Thromb Haemost 1999; 81: 667.Google Scholar
54.Kohler, M, Hellstern, P, Lechler, E, Uberfuhr, P, Muller-Berghaus, G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 1998; 80: 399–402.Google Scholar
55.Hellstern, P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res 1999; 95: S7–S12.Google Scholar
56.Kohler, M, Habauer, G, Miyashita, C et al. . Quality control of prothrombin complex preparations: in vivo and in vitro findings. Beitr Infusionsther 1990; 26: 186–189.Google ScholarPubMed
57.Erhardtsen, E, Nony, P, Dechavanne, M, Ffrench, P, Boissel, JP, Hedner, U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9: 741–748.CrossRefGoogle Scholar
58.Freeman, WD, Brott, TG, Barrett, KM et al. . Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004; 79: 1495–1500.CrossRefGoogle ScholarPubMed
59.Conti, S, La Torre, D, Gambelunghe, G, Ciorba, E, Iorio, A. Successful treatment with rFVIIa of spontaneous intracerebral hemorrhage in a patient with mechanical prosthetic heart valves. Clin Lab Haem 2005; 27: 283–285.CrossRefGoogle Scholar